HALO
NASDAQ
US
Halozyme Therapeutics, Inc. - Common Stock
$64,49
▼ $-0,91
(-1,39%)
Vol. 1.5M
12
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$7.9B
P/E
13,3
ROE
141,6%
Margine
47,9%
D/E
299,80
Beta
0,97
52W
$47–$80
Consenso Wall Street
15 analisti · Apr 20262
Acquisto forte
9
Compra
3
Mantieni
1
Vendi
0
Vendita forte
73,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $2,24 | $-0,24 | $-2,48 |
| Set 2025 | $1,66 | $1,72 | +$0,06 |
| Giu 2025 | $1,29 | $1,54 | +$0,25 |
| Mar 2025 | $0,97 | $1,11 | +$0,14 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| Utile netto | — | $137.0M | $118.1M | $165.2M | $175.2M | -$141.6M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 136.6% | 136.6% | 136.6% | 136.6% | 141.6% | 141.6% |
| P/E (TTM) | 11.50 | 14.64 | 15.81 | 13.68 | 13.14 | 13.29 |
| Net Margin | 50.7% | 47.3% | 47.3% | 47.3% | 47.9% | 47.9% |
| Gross Margin | 85.8% | 84.2% | 84.2% | 84.2% | 84.5% | 84.5% |
| D/E Ratio | 453.53 | 453.53 | 453.53 | 453.53 | 299.80 | 299.80 |
| Current Ratio | 8.36 | 8.36 | 8.36 | 8.36 | 1.59 | 1.59 |
Rapporti chiave
ROA (TTM)
27,9%
P/S (TTM)
6,37
P/B
16,7
EPS (TTM)
$4,76
CF/Share
$2,37
Crescita ricavi 3A
+31,8%
52W High
$79,50
52W Low
$46,76
$46,76
Intervallo 52 settimane
$79,50
Salute finanziaria
Flusso di cassa libero
-$70.2M
Debito netto
$2.0B
Liquidità
$133.8M
Debito totale
$2.1B
Aggiornato al Dic 31, 2025
Як HALO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка HALO vs аналоги Biotechnology
P/E
13,3
▼
29%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
6,4
▼
50%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
16,7
▲
580%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість HALO vs аналоги Biotechnology
ROE
141,6%
▲
310%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
47,9%
▲
117%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
84,6%
▲
8%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
27,9%
▲
160%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя HALO vs аналоги Biotechnology
D/E ratio
299,8
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,6
▼
64%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,0
▼
0%
sotto
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів HALO
HALO
Mediana peer
Industria
HALO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
HALO vs аналоги: ключові метрики
Segnali Correlati
Ultima opinione AI
Grok
BUY
Price action shows a significant pullback from the February 2026 high of $82.22 to the current $64.19, representing about a 22% dip, which appears to be testing support around $62-64 seen in prior lows, making this a potentially attractive entry …
Mar 23, 2026Ultime notizie
Nessuna notizia correlata ancora